NYSE:CLB - Core Laboratories Stock Price, Forecast & News

Core Laboratories trades on the New York Stock Exchange (NYSE) under the ticker symbol "CLB."

Core Laboratories announced a quarterly dividend on Wednesday, January 15th. Shareholders of record on Friday, January 24th will be given a dividend of $0.25 per share on Friday, February 14th. This represents a $1.00 dividend on an annualized basis and a yield of 2.96%. The ex-dividend date is Thursday, January 23rd. View Core Laboratories' Dividend History.

Core Laboratories (NYSE:CLB) released its earnings results on Wednesday, January, 29th. The oil and gas company reported $0.38 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of $0.37 by $0.01. The oil and gas company earned $157 million during the quarter, compared to analyst estimates of $155.31 million. The firm's revenue for the quarter was down 9.4% compared to the same quarter last year. During the same quarter last year, the business posted $0.48 EPS. View Core Laboratories' Earnings History.

Core Laboratories is scheduled to release their next quarterly earnings announcement on Wednesday, April 22nd 2020. View Earnings Estimates for Core Laboratories.

Core Laboratories updated its first quarter earnings guidance on Wednesday, January, 29th. The company provided EPS guidance of $0.39-0.41 for the period, compared to the Thomson Reuters consensus estimate of $0.39. The company issued revenue guidance of $159-164 million, compared to the consensus revenue estimate of $159.64 million.

13 brokerages have issued 1 year price objectives for Core Laboratories' shares. Their forecasts range from $36.00 to $77.00. On average, they anticipate Core Laboratories' stock price to reach $47.86 in the next year. This suggests a possible upside of 41.8% from the stock's current price. View Analyst Price Targets for Core Laboratories.

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Core Laboratories in the last year. There are currently 9 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Core Laboratories.

News coverage about CLB stock has trended neutral recently, according to InfoTrie Sentiment. The research firm identifies positive and negative press coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Core Laboratories earned a news impact score of 0.2 on InfoTrie's scale. They also gave media coverage about the oil and gas company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View News Stories for Core Laboratories.

Core Laboratories saw a increase in short interest in January. As of January 31st, there was short interest totalling 3,660,000 shares, an increase of 29.3% from the January 15th total of 2,830,000 shares. Based on an average trading volume of 696,500 shares, the short-interest ratio is currently 5.3 days. Approximately 8.4% of the shares of the company are short sold. View Core Laboratories' Current Options Chain.

Based on aggregate information from My MarketBeat watchlists, some companies that other Core Laboratories investors own include CA (CA), BlackRock (BLK), Endologix (ELGX), Chipotle Mexican Grill (CMG), Starbucks (SBUX), Micron Technology (MU), AT&T (T), Baidu (BIDU), NIC (EGOV) and Netflix (NFLX).

Core Laboratories' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Massachusetts Financial Services Co. MA (10.70%), Earnest Partners LLC (6.61%), Van ECK Associates Corp (5.67%), Kayne Anderson Rudnick Investment Management LLC (3.45%), Mairs & Power INC (2.28%) and Bank of New York Mellon Corp (1.74%). Company insiders that own Core Laboratories stock include Gregory Barry Barnett, Jan Willem Sodderland, Kevin Daniels, Lawrence Bruno and Mark F Elvig. View Institutional Ownership Trends for Core Laboratories.

CLB stock was sold by a variety of institutional investors in the last quarter, including Granite Investment Partners LLC, Manning & Napier Group LLC, Kayne Anderson Rudnick Investment Management LLC, Eaton Vance Management, Schroder Investment Management Group, Penn Capital Management Co. Inc., Evercore Wealth Management LLC and New York State Common Retirement Fund. Company insiders that have sold Core Laboratories company stock in the last year include Kevin Daniels and Mark F Elvig. View Insider Buying and Selling for Core Laboratories.

CLB stock was bought by a variety of institutional investors in the last quarter, including Van ECK Associates Corp, C Partners Holding GmbH, Thrivent Financial for Lutherans, Mairs & Power INC, Teacher Retirement System of Texas, Douglas Lane & Associates LLC, Bank of Montreal Can and Earnest Partners LLC. Company insiders that have bought Core Laboratories stock in the last two years include Gregory Barry Barnett, Jan Willem Sodderland and Lawrence Bruno. View Insider Buying and Selling for Core Laboratories.

Shares of CLB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of CLB stock can currently be purchased for approximately $33.75.